Idiopathic Parkinson's Disease Clinical Trial
Official title:
Vascular Abnormalities in Idiopathic Parkinson's Disease
The purpose of this study is to use non-invasive Magnetic Resonance Imaging (MRI) scans to
investigate venous insufficiency, brain iron levels and white matter hyperintensities (WMHs)
to determine if there is direct correlation with Idiopathic Parkinson's Disease (IPD).
Idiopathic Parkinson's disease (IPD) is the second most common neurodegenerative disease
after Alzheimer's disease and it affects roughly 0.1% to 0.3% of the population. The risk of
having IPD increases with age and the median onset age is about 60 years. The etiology of
IPD remains unknown. Generally, Parkinson's patients show a reduction of dopamine levels in
the deep grey matter of the brain over time. Many clinically diagnosed cases of IPD are
associated with white matter hyperintensities (WMH) and elevated brain iron levels.
Furthermore, in the last few years there has been an increasing interest in the role of
veins in neurodegenerative diseases. More attention has been paid to the extracranial veins
as being potential sources of venous hypertension. The obstructed veins are thought to cause
venous insufficiency. By using MRI techniques, the investigators can not only obtain
qualitative vascular information but also quantitative arterial and venous blood flow
measurements.
Experimental plans: All patients and controls will consent to be subjects in this study.
Data will be collected on the Siemens Skyra 3T scanner at the University of Saskatchewan
using a 16 channel head/neck coil arrangement. The investigators main approach in this
research is to collect MR data on the vasculature in the brain and neck, the iron content in
the brain, and standard anatomical scans for 20 patients with idiopathic Parkinson's disease
and 10 age matched normal subjects. MR venography, flow quantification and susceptibility
weighted imaging will be used.
Anatomic MR venography (MRV): Contrast enhanced MRV is widely regarded as the optimal method
for evaluation of disease involving the dural venous sinuses. It is an accurate, reliable
and robust method for assessing sino-venous pathology such as thrombosis and tumor invasion.
MRV is also able to demonstrate pathology involving larger cerebral veins. The investigators
will be able to record both anatomic variants as well as any stenosis. Extracranially, the
investigators will look for any significant variants or stenosis affecting the jugular
venous system, the vertebral venous system and the azygous system. Data will be analyzed to
separately display and evaluate the structure of arteries and veins in the head and neck.
The maximum intensity projection (MIP) of the whole series will be generated in the coronal
view. The major arteries will be evaluated as well as major veins of interest for the
structural analysis including the transverse sinuses, the internal and external jugular
veins, vertebral veins and deep cervical veins which usually serve as collaterals in case of
flow abnormalities in the jugular veins. Cross sectional areas (CSA) of suspicious stenotic
regions will also be measured to validate whether the variation seen in these CSA are veins
stenosis or not.
Flow quantification (FQ): Pathological change in cerebrospinal venous drainage will be
reflected by upstream disturbance of venous flow. Phase contrast MR flow techniques allow
the investigators to interrogate venous flow. By applying FQ techniques to the dural venous
sinuses, investigators hope to characterize the interplay between anatomic venous
obstruction and pathologically altered drainage. By understanding this relationship, the
investigators can gain deeper insight into the mechanism by which cerebrospinal venous
insufficiency interacts with iron homeostasis mechanisms and ultimately with the
pathogenesis of Parkinson's disease. Dural sinus hemodynamics can be studied non-invasively
with phase contrast FQ. The phase contrast flow quantification (PCFQ) images will be used to
analyze the through-plane cerebral spinal fluid in the neck (C2/C3 level), as well as blood
flow in the neck (C2/C3 and C6/C7 levels), the superior sagittal sinus (SSS), both left and
right transverse sinus, the straight sinus, both the extra cranial jugular and vertebral
veins and Dural Sinus. Areas of interest will be drawn around the veins and arteries of
interest and flow will be calculated over a full cardiac cycle. Thirty time points will be
collected for each cardiac cycle by using a retroactive pulse trigger. The vessels of
interest will include: the internal and external jugular veins (IJVs, EJVs), vertebral
veins, deep cervical veins, common carotid arteries and vertebral arteries. The
investigators will be evaluating the integrated flow, the average velocity, the volume flow
rate, as well as negative and positive flow rate. This will be assessed in the cervical
arteries to compare the inflow and outflow of the brain. Abnormalities may be identified by
stressing the system, i.e., with a breath hold. Finally a large number of quantitative
measures will be made on all the arteries and veins in the neck to assess both individual
variants and total flow in the brain.
Measuring Iron in the basal ganglia and thalamus using Susceptibility Weighted Imaging
(SWI): A presence of iron not only in lesions, but now more importantly in the basal ganglia
and thalamus has been shown in IPD patients. The latter shows iron build up at the
confluence of the draining veins in these areas. SWI can be run to show iron deposition in
several areas of interest within the brain. SWI has very high spatial resolution and is an
optimal method to study the small internal cerebral venous system. The ability to measure
the amount of non-heme iron in the brain will facilitate a better understanding of the
disease progression and may help in predicting the treatment outcome. Iron deposition will
be evaluated from the SWI images. To measure iron content in grey matter, investigators will
look at iron in the following eight regions: caudate nucleus, globus pallidus, putamen,
thalamus, pulvinar thalamus (as it appears to be affected much before the rest of the
thalamus), substantia nigra, red nucleus and dentate nucleus. For each deep gray matter
structure, two major regions of interest will be analyzed: the entire object drawn manually
and the region-of-interest that has much higher iron content. The investigators will provide
the following information for these regions: iron content in the abnormal part of the
structure (the investigators refer to this as the high iron content region); the area of
this region; the average iron per pixel in this region; and also the investigators will
quote the same three values for the total iron in these structures.
;
Observational Model: Case Control, Time Perspective: Retrospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03665493 -
Dopamine Effect on Inhibitory Control
|
N/A | |
Completed |
NCT02227355 -
Evaluating the Effectiveness of Neupro® (Rotigotine) and L-dopa Combination Therapy in Patients With Parkinson's Disease
|
N/A | |
Completed |
NCT01026428 -
A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics
|
Phase 1/Phase 2 | |
Completed |
NCT00664157 -
Facial Expression Recognition of Emotion and Categorization of Emotional Words in Parkinson's Disease. Impact of L-Dopa and Deep Brain Stimulation of Subthalamic Nucleus
|
N/A | |
Completed |
NCT04524143 -
The Acute Effect of Cervical Mobilization in Parkinson's Disease
|
N/A | |
Completed |
NCT05107531 -
Investigation of Gait, Foot Pressure Distribution and Balance in Parkinson's Patients With Motor Freezing
|
||
Completed |
NCT04524182 -
The Acute Effect of Lumbosacral Mobilization in Parkinson's Disease
|
N/A | |
Completed |
NCT00985517 -
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT01968031 -
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
|
Phase 3 | |
Completed |
NCT01970813 -
Efficacy of Acupuncture and Bee Venom Acupuncture on Patients With Idiopathic Parkinson's Disease
|
N/A | |
Completed |
NCT01221948 -
Vercise Implantable Stimulator for Treating Parkinson's Disease
|
Phase 2 | |
Terminated |
NCT01028586 -
MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)
|
Phase 3 | |
Completed |
NCT00239564 -
Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02240030 -
Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
|
Phase 3 | |
Completed |
NCT00605683 -
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
|
Phase 3 | |
Completed |
NCT00400634 -
Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease
|
Phase 2 | |
Completed |
NCT01227265 -
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)
|
Phase 3 | |
Completed |
NCT02565628 -
PF-06669571 In Subjects With Idiopathic Parkinson's Disease
|
Phase 1 | |
Completed |
NCT01617135 -
Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes
|
Phase 2 | |
Completed |
NCT01606670 -
Observational Study With Neupro® to Evaluate the Patient´s Perception of Pain Associated With Parkinson´s Disease
|